Arroyo V
Liver Unit, Institute of Digestive Diseases, Hospital Clinic, University of Barcelona, Spain.
Aliment Pharmacol Ther. 2002 Dec;16 Suppl 5:1-5. doi: 10.1046/j.1365-2036.16.s5.1.x.
Albumin was introduced initially in the treatment of patients with cirrhosis and ascites to increase serum albumin concentration due to its oncotic effect. Although its administration declined some years later, at present it constitutes an essential treatment in clinical hepatology. Several studies have clearly demonstrated its efficacy in the prevention and treatment of circulatory dysfunction and hepatorenal syndrome in patients with cirrhosis. These effects can be due not only to its properties as a plasma expander but also to its capacity to bind numerous substances such as bile acids, nitric oxide and cytokines. Based on this capacity an albumin dialysis system (MARS) has recently been developed. The usefulness of this system in the management of patients with acute and chronic liver failure is, at present, under evaluation.
白蛋白最初被用于治疗肝硬化和腹水患者,因其具有胶体渗透压效应可提高血清白蛋白浓度。尽管几年后其使用量有所下降,但目前它仍是临床肝病学中的一种重要治疗方法。多项研究已明确证实其在预防和治疗肝硬化患者循环功能障碍及肝肾综合征方面的疗效。这些作用不仅归因于其作为血浆扩容剂的特性,还归因于其结合多种物质(如胆汁酸、一氧化氮和细胞因子)的能力。基于这种能力,最近开发了一种白蛋白透析系统(分子吸附再循环系统)。目前,该系统在急性和慢性肝衰竭患者管理中的实用性正在评估中。